Latest news with #iPSC
National Post
28-07-2025
- Business
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content
Yahoo
23-07-2025
- Business
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
Associated Press
24-06-2025
- Health
- Associated Press
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
Watertown, MA June 24, 2025 --( )-- The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. This milestone is made possible through a new supply agreement with Axol Bioscience Ltd., a leading provider of iPSC-derived cells and services. These iPSC lines, developed by ALS TDI from samples generously donated by participants in the ALS Research Collaborative (ARC) Study, represent both genetic and sporadic forms of ALS. They include key ALS-associated mutations such as C9orf72, SOD1, and TDP-43, and will be used to generate ALS-relevant cell types—including motor neurons, microglia, and astrocytes—for use in drug discovery and disease modeling. The goal of this collaboration is to provide high-quality research tools to the global scientific community, including academic and pharmaceutical researchers, to help further the understanding and development of treatments for ALS. 'This is a major step forward for ALS research,' said Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. 'By making these iPSC-derived cells broadly accessible through Axol's infrastructure, we are ensuring that the contributions of people with ALS who shared their samples and data through ARC can drive discoveries in labs across the globe.' ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available today. These cells are derived from real people living with ALS, many of whom also shared clinical data, creating a uniquely valuable resource for understanding disease mechanisms and testing potential treatments. Through this agreement, Axol will manufacture and distribute iPSC-derived cells to academic and industry researchers worldwide, ensuring quality, consistency, and scalability. The goal, to accelerate progress across the ALS field by providing powerful, human-relevant tools that better reflect the diversity and complexity of the disease. 'Collaborating with ALS-TDI allows us to broaden access to highly disease-relevant iPSC models of ALS, which are vital for understanding disease mechanisms and accelerating therapeutic discovery for patients and their families,' said Liam Taylor, CEO of Axol Bioscience. 'This partnership aligns with our mission to build and enable better human disease models by providing high-quality, human-relevant cells and models that advance neuroscience research and drug development.' ALS TDI extends its deepest thanks to every person living with ALS who contributed to this effort. Their willingness to share samples and data through the ARC Study has made this breakthrough possible. To learn more about the ALS Research Collaborative, visit For more information, please contact: Axol Bioscience Duncan Borthwick [email protected] ALS Therapy Development Institute Fernando Vieira [email protected] About Axol Bioscience Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. Axol has a deep connection with the ALS research community and works to support the creation of more human relevant in vitro models to accelerate discovery and therapeutic development. About ALS Therapy Development Institute (ALS TDI) The ALS Therapy Development Institute (ALS TDI) is the world's first and largest nonprofit biotech dedicated solely to discovering and developing effective treatments for ALS. Based in Watertown, Massachusetts, ALS TDI runs a state-of-the-art research center and leads the ALS Research Collaborative (ARC)—one of the most comprehensive and longest-running natural history studies in ALS. Through innovative, patient-driven science, ALS TDI is working to end ALS for everyone affected by this devastating disease. Contact Information: ALS Therapy Development Institute Meghan Lawlor (978)729-2961 Contact via Email Read the full story here: ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research Press Release Distributed by
Associated Press
16-06-2025
- Business
- Associated Press
uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development
ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene's proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications reprogramming diagram uBriGene's iPSC seed banks and master cell banks (MCBs) are generated in GMP-compliant cleanrooms using healthy donor fibroblasts sourced from the USA in full compliance with FDA regulations. Reprogrammed with a non-integrating mRNA-LNP kit, the iPSCs are free of genomic footprint and residual RNA. Each bank undergoes rigorous quality control testing to confirm identity, genomic stability, sterility, the absence of adventitious viruses, and strong expression of stemness and pluripotency markers. Early-passage seed banks (P2-P5) and clonally derived MCBs are cryopreserved and released for use in a wide range of regenerative and allogeneic cell therapy programs. 'With our iPSC banks, clients can save 1-2 years and the uncertainty associated with donor cell sourcing and reprogramming,' said Dr. Xiulian Sun, CTO and Founder at uBriGene. 'These banks are designed to accelerate preclinical and clinical workflows with regulatory confidence.' uBriGene's iPSC banks are now available in both research-use only (RUO) and GMP-compliant formats. Gene editing services are also available upon request to customize cell lines for disease modeling or therapeutic development. To learn more about uBriGene's iPSC bank offerings, visit: About uBriGene Founded in 2015, uBriGene Biosciences is a leading Contract Development and Manufacturing Organization for advanced therapeutic medicinal products (ATMPs). The company provides integrated CDMO and CRO solutions, encompassing services for cell therapy products, viral vectors, and RNA-related products, with in-house QC testing and regulatory IND filing. Our GMP-validated Maryland facility offers one-stop CDMO services from process development to manufacturing, driving global advancements in ATMPs. Contact InformationMingjuan Liu Director of Marketing 800 663 2528 SOURCE: UBRIGENE BIOSCIENCES INC press release
Yahoo
27-05-2025
- Business
- Yahoo
Induced Pluripotent Stem Cell (iPSC) Industry Report 2025-2030: iPSCs Set to Redefine Clinical and Research Paradigms, iPSC Technology Drives Innovation in Regenerative Therapy
Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" has been added to offering. The market for iPSC-derived products continues expanding with involvement from companies like Lonza, BD Biosciences, and Thermo Fisher Scientific, among others. Over 90 companies actively engage in this market, offering diverse products and technologies for research and therapeutic applications. Since discovering iPSCs 18 years ago, remarkable advancements have occurred. It saw its first human application in 2013, and now at least 155 clinical trials use iPSCs globally. iPSCs are being tested for various conditions, including Parkinson's disease, cancer immunotherapies with iNK cells, age-related macular degeneration, and Type 1 diabetes. This diversity underscores iPSCs' transformative potential in treating numerous diseases. Commercially, companies harness iPSC products for drug development, disease modeling, and toxicology testing. Notable players include FUJIFILM Cellular Dynamics International (FCDI), a leader in iPSC-derived human cell production, and ReproCELL, pioneering iPSC product commercialization. Europe also hosts major competitors like Evotec and Ncardia, specializing in drug screening and cardiac applications, respectively. The potential of iPSCs to redefine medicine and biotechnology is substantial. As iPSC applications evolve in disease modeling, drug discovery, and cell therapies, they drive innovation within healthcare and research, paving the way for transformative advancements. This comprehensive report outlines key players, strategic partnerships, and innovations propelling the sector. It details advancements in iPSC research, manufacturing, and clinical developments, alongside an analysis of the funding landscape. Projected market growth rates through 2030, categorized by application, technology, cell types, and geography, offer insights into iPSC industry's future. Current Commercialization Methods of iPSCs: Cellular Therapy: iPSCs are being explored for cell therapy applications to repair injuries or cure diseases by substituting damaged cells. Disease Modeling: Patient-specific iPSCs are differentiated into disease-specific cells, creating functional models for research. Drug Development: iPSCs deliver physiologically relevant cells for drug discovery, enhancing the efficacy of compound identification, target validation, and screening processes. Personalized Medicine: Integration with genome-editing technologies facilitates customized treatments by modifying iPSCs at the genetic level. Toxicology Testing: Screening iPSCs or derivatives to evaluate compound safety and efficacy reduces dependence on animal testing. Tissue Engineering: Culturing iPSCs on biocompatible scaffolds supports engineered tissue development for transplantation. Organoid Production: Self-organizing iPSCs form 3D organoids, facilitating organ study, disease modeling, and drug testing. Gene Editing: Techniques like CRISPR enable iPSC modifications for mutation correction, facilitating functional cell development for treatments. Research Tools: Extensive research applications include studying cellular processes and testing experimental therapies with iPSCs. Stem Cell Banking: iPSC repositories offer diverse cell types for research, allowing investigations into conditions using samples from various donors. Cultured Meat Production: iPSCs serve as cellular bases for lab-grown meat production, promoting sustainable alternatives. 3D Bioprinting: Differentiated iPSCs are used in bioinks for creating complex tissue structures via 3D bioprinting. Key Topics Covered: 1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary 2. INTRODUCTION 3. CURRENT STATUS OF IPSC INDUSTRY3.1 Progress made in Autologous Cell Therapy using iPSCs3.2 Allogeneic iPSC-based Cell Therapies3.3 Share of iPSC-based Research within the Overall Stem Cell Industry3.4 Major Focus Areas of iPSC Companies3.5 Commercially Available iPSC-derived Cell Types3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays3.7 iPSC-derived Cell Types used in Clinical Trials3.8 Currently Available iPSC Technologies 4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)4.1 First iPSC Generation from Mouse Fibroblasts, 20064.2 First Human iPSC Generation, 20074.3 Creation of CiRA, 20104.4 First High-Throughput Screening using iPSCs, 20124.5 First iPSC Clinical Trial Approved in Japan, 20134.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 20144.7 EBiSC Founded, 20144.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20174.9 Clinical Trial for Parkinson's Disease using Allogeneic iPSCs, 20184.10 Commercial iPSC Plant SMaRT Established, 20184.11 First iPSC Therapy Center in Japan, 20194.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 20194.13 Cynata Therapeutics' World's Largest Phase III Clinical Trial, 20204.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 20214.15 Production of in-house iPSCs using Peripheral Blood Cells, 2022 5. RESEARCH PUBLICATIONS ON IPSCS5.1 Rapid Growth in iPSC Publications 6. IPSC: PATENT LANDSCAPE ANALYSIS6.1 iPSC Patent Applications by Jurisdiction6.2 iPSC Patent Applicants6.3 Inventors of iPSC Patents6.4 iPSC Patent Owners6.5 Legal Status of iPSC Patents 7. IPSC: CLINICAL TRIAL LANDSCAPE7.1 Number of iPSC Clinical Trials7.1 Recruitment Status of iPSC Clinical Trials7.3 iPSC Clinical Trials Stydy Designs7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials7.5 iPSC-based Trials by Phase of Study7.6 iPSC Clinical Trials by Funder Type7.7 Geographic Distribution of iPSC-based Clinical Trials7.8 Promising iPSC Product Candidates7.9 Companies having Preclinical iPSC Assets 8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR8.1 Mergers and Acquisitions (M&A) Sector8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector8.3 Venture Capital Funding in iPSC Sector 9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)9.1 OSKM Cocktail9.2 Pluripotency-Associated Transcription Factors and their Functions9.3 Delivery of Reprogramming Factors9.4 Genome Editing Technologies in iPSC Generation9.5 Available iPSC Lines and their applications 10. HUMAN IPSC BANKING10.1 Major Biobanks Storing iPSCs & iPSC Lines10.2 Cell Sources for iPSC Banks10.3 Reprogramming Methods in iPSC Banks10.4 Ownership and Investments made in iPSC Banks 11. BIOMEDICAL APPLICATIONS OF IPSCs11.1 iPSCs in Basic Research11.2 Applications of iPSCs in Drug Discovery11.3 Applications of iPSCs in Toxicology Studies11.4 Applications of iPSCs in Disease Modeling11.5 Applications of iPSCs in Cell-Based Therapies11.6 Other Novel Applications of iPSCs 12. MARKET ANALYSIS12.1 Global Market for iPSCs by Geography12.2 Global Market for iPSCs by Technology12.3 Global Market for iPSCs by Biomedical Application12.4 Global Market for iPSCs by Derived Cell Type12.5 Market Drivers12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
